Form D · Biotechnology
BioMotiv, LLC
Cleveland, OH · CIK 0001557499
Offering snapshot reported Aug 1, 2018 · SEC filing
- Reported sold
- $146M Offering amount: $200M
- Investors reported
- 62 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 22, 2012 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 1, 2018 | Amendment | $145,726,790 | $0vs Aug 4, 2017 | 62 | SEC filing |
| Aug 4, 2017 | Amendment | $145,726,790 | $124,726,790vs Sep 5, 2012 | 62 | SEC filing |
| Aug 5, 2016 | Amendment | $144,676,790 | $63,250,000vs Aug 6, 2015 | 62 | SEC filing |
| Aug 6, 2015 | Amendment | $81,426,790 | $30,450,000vs Aug 7, 2014 | 57 | SEC filing |
| Aug 7, 2014 | Amendment | $50,976,790 | $4,782,235vs Aug 6, 2013 | 54 | SEC filing |
| Aug 6, 2013 | Amendment | $46,194,555 | $25,194,555vs Sep 5, 2012 | 47 | SEC filing |
| Sep 5, 2012 | Initial | $21,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-183660
Source: Form D, filed Aug 1, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
The linked fund shows its most recently reported ADV details.
Matched by reported Form D file number
BIOMOTIV LLC
Investment adviser: ADVENT LIFE SCIENCES LLP
- Gross asset value
- $27.9M
- Beneficial owners
- 84
- ADV minimum commitment
- $250K
Reported in Form ADV on Mar 26, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.
Service providers
Provider details
- Annual audit
- Yes
- Prime brokers
- No
- Custodians
- No
- Administrator other than the adviser
- No
- External marketing
- No
EISNER AMPER
PCAOB 274
Filing source
Form ADV 2072193 · Mar 26, 2026 · Schedule D 7.B.(1), fund 805-6862260237
Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carmen Bozic, Md | Director |
| Carmen Bozic, M.D. | Director |
| Achilles A. Demetriou, M.D., Ph.D. Facs | Director |
| Jeffrey Edelson, Md | Executive |
| Ronald G. Harrington | Director |
| Graeme Martin | Director |
| Graeme Martin, Ph.D. | Director |
| Michael Martin, Ph.D. | Director |
| Charles Mc Osker, Ph.D. | Executive |
| Robert S. Reitman | Director |
| Baiju R. Shah | Director, Executive |
| Jonathan S. Stamler, M.D. | Director |
| Stacie Switzer | Executive |
| Mark Teague | Executive |
| Theodore Torphy, Ph.D. | Executive |
| Ted Torphy, Ph.D. | Executive |
| David C. U'prichard, Ph.D. | Director |
| Terry Vance | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:Cleveland, OH, 44122